Ken Yamada
Associate Director, Novartis
Ken Yamada is listed as Associate Director, Novartis. Ken is scheduled to speak at SLAS 2027 International Conference & Exhibition on 3 February 2027.
Compiled from published conference agendas; not yet confirmed by Ken. Is this you? Claim this profile.
About
Ken Yamada is Associate Director of Frontier Chemistry at Novartis Biomedical Research in Cambridge MA. Ken obtained B.S. in chemistry at Brown University, M.S. in organic chemistry at UCLA, and PhD at University of Tokyo under guidance of Prof. Tohru Fukuyama. He has over 20 years of experience in drug discovery at Novartis and Yamanouchi (now Astellas) combined. Ken has contributed to and led small molecule projects leading to a number of development candidates and clinical stage molecules in cardiovascular, immunology and hematology indications. In the past decade, Ken’s research interests evolved around drugging the undruggables by combination of novel modalities and technologies. In particular, he was an early adaptor of TPD at Novartis and, to harness its full potential, spearheaded an internal incubator project that built microfluidic-based phenotypic DEL platform from ground up. Most recently, Ken co-led the efforts to leverage AI/ML to accelerate medicinal chemistry at Novarti